Arrowhead Pharmaceuticals · 7 hours ago
Associate Scientist I, Small Scale Synthesis
Madison, WI
Full-time
Onsite
New Grad, Entry Level
$60K/yr - $70K/yr
0+ years expArrowhead Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing innovative drugs for diseases with a genetic basis. The Associate Scientist I will primarily focus on oligonucleotide synthesis, purification, and analytical chemistry, contributing to the success of the company's programs.
BiotechnologyHealth CareNanotechnologyPharmaceutical
Responsibilities
Maintain a well-documented laboratory notebook
Track progress against project timelines, generate regular status updates, and communicate progress and issues to management
Manage time effectively to meet deadlines
Adhere to safe laboratory practices
Perform synthesis, purification, and analysis of oligonucleotides
Assist with maintenance of bioconjugate and oligonucleotide inventory
Qualification
Required
B.S. Chemistry or Biochemistry degree with excellent understanding of organic and analytical chemistry
0-2 years of experience working in a chemistry laboratory
Experience with a wide range of analytical techniques, especially HPLC
Ability to quickly learn new procedures and techniques
Preferred
Experience working with large molecule synthetic targets (especially oligonucleotides) either in an academic or industry setting
Previous experience working in pharmaceutical setting
Benefits
Competitive salaries
Excellent benefit package
Company
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
501-1000 employees
H1B Sponsorship
Arrowhead Pharmaceuticals has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (4)
2024 (5)
2023 (1)
2022 (5)
2020 (1)
Funding
Current Stage
Public CompanyTotal Funding
$1.62BKey Investors
Sarepta TherapeuticsSixth StreetSilence Therapeutics
2024-11-26Post Ipo Equity· $325M
2024-08-08Post Ipo Debt· $400M
2024-01-03Post Ipo Equity· $450M
Leadership Team
Christopher Anzalone
President and Chief Executive Officer
Bruce Given
Chief Operating Officer
Recent News
2025-12-27
Los Angeles Business Journal
2025-12-24
Morningstar.com
2025-12-16
Company data provided by crunchbase